Peregrine Pharmaceuticals Receives FDA Fast Track Designation for Its Immunotherapy Bavituximab as a Potential Treatment of Second-Line Non-Small Cell Lung Cancer|
Peregrine Pharmaceuticals, Inc. announced that the company has received Fast Track designation by the U.S. Food and Drug Administration (FDA) for its lead investigational immunotherapy bavituximab for the potential treatment of second-line non-small cell lung cancer. [Peregrine Pharmaceuticals, Inc.]
AIT Announces Phase II Study of NOxCureCF, a Respiratory Treatment for Cystic Fibrosis Patients Using a Nitric Oxide-Base Formulation
Advanced Inhalation Therapies announced that it has begun enrollment in Israel for a multicenter, open label, Phase II clinical trial of NOxCureCF, a respiratory treatment for patients with cystic fibrosis. [PR Newswire Association LLC]
Ludwig Cancer Research Bestows Half a Billion in New Funding to Six Eminent U.S. Research Institutions
Cancer research in the U.S. got a critical boost as the six Ludwig Centers at Johns Hopkins University, Harvard University, the Massachusetts Institute of Technology, Memorial Sloan-Kettering Cancer Center, Stanford University and the University of Chicago received a total of $540 million as part of a gift from Ludwig Cancer Research, on behalf of its founder, Daniel K. Ludwig. [Ludwig Institute for Cancer Research Ltd]
Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!
Comments or Suggestions? Submit your feedback here.